Harvard Bioscience (NASDAQ:HBIO) Stock Crosses Below 200 Day Moving Average – Time to Sell?

Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.56 and traded as low as $0.5575. Harvard Bioscience shares last traded at $0.5674, with a volume of 335,061 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Zacks Research raised Harvard Bioscience to a “hold” rating in a research report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Monday, December 29th. Finally, Wall Street Zen raised shares of Harvard Bioscience from a “hold” rating to a “buy” rating in a research report on Monday, November 17th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $2.00.

Harvard Bioscience Trading Down 2.7%

The company has a market cap of $25.37 million, a P/E ratio of -0.47 and a beta of 1.55. The business has a 50 day moving average price of $0.61 and a 200-day moving average price of $0.56.

Institutional Investors Weigh In On Harvard Bioscience

Institutional investors and hedge funds have recently modified their holdings of the company. AMH Equity Ltd lifted its stake in Harvard Bioscience by 15.4% in the 3rd quarter. AMH Equity Ltd now owns 4,047,535 shares of the medical instruments supplier’s stock valued at $1,775,000 after purchasing an additional 538,832 shares during the last quarter. Weber Capital Management LLC ADV bought a new stake in Harvard Bioscience in the fourth quarter valued at approximately $2,140,000. Meros Investment Management LP lifted its position in shares of Harvard Bioscience by 32.6% in the fourth quarter. Meros Investment Management LP now owns 1,217,628 shares of the medical instruments supplier’s stock valued at $814,000 after buying an additional 299,369 shares during the last quarter. Corsair Capital Management L.P. boosted its stake in shares of Harvard Bioscience by 1,008.7% during the 4th quarter. Corsair Capital Management L.P. now owns 1,108,692 shares of the medical instruments supplier’s stock worth $741,000 after acquiring an additional 1,008,692 shares during the period. Finally, Acadian Asset Management LLC increased its holdings in shares of Harvard Bioscience by 7.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,077,069 shares of the medical instruments supplier’s stock worth $606,000 after acquiring an additional 78,276 shares during the last quarter. 80.87% of the stock is owned by institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.